For research use only. Not for therapeutic Use.
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC)[1][2].
AME-133v (0.027-20 μg/mL) concentration-dependently inhibits the binding of biotinylated Rituximab to CD20 in SKW6.4 cells[1].
| Catalog Number | I042410 |
| CAS Number | 1169956-08-4 |
| Purity | ≥95% |
| Reference | [1]. Forero-Torres A, et, al. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012 Mar 1;18(5):1395-403. [2]. Cheney CM, et, al. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs. 2014 May-Jun;6(3):749-55. |
